摘要
目的探讨泛福舒治疗反复呼吸道感染患儿的临床效果。方法选取2011年4月-2013年5月反复呼吸道感染患儿140例,随机分为对照组67例、观察组73例,对照组患儿实施常规抗感染治疗,观察组患儿在对照组基础上加用泛福舒口服,于治疗7d时对两组患儿治疗效果进行评价,数据采用SPSS13.0软件进行统计分析。结果治疗总有效率观察组为94.52%,明显高于对照组的80.60%,两组比较差异有统计学意义(P<0.05);观察组患儿体温下降、呼吸道症状缓解、肺部啰音消失时间分别为(1.68±0.52)d、(2.54±0.73)d和(4.38±1.42)d,均明显短于对照组的(2.26±0.65)d、(3.93±0.75)d和(6.67±0.92)d,随访6个月,观察组呼吸道感染再次发作次数为(1.80±0.55)次,明显少于对照组的(6.92±1.72)次,上述两组比较差异有统计学意义(P<0.05);对照组患儿血清免疫球蛋白各指标水平与治疗前相比均无明显改变,观察组患儿IgG水平为(7.35±0.59)g/L,与治疗前(5.41±0.84)g/L相比明显提高,差异有统计学意义(P<0.05),其他指标与治疗前相比无明显改变,治疗后观察组患儿IgG水平明显高于对照组(5.62±0.57)g/L的水平,两组患儿比较差异有统计学意义(P<0.05)。结论使用泛福舒治疗小儿反复呼吸道感染,有利于提高患儿免疫力、缩短疗程、改善预后、给药方便,容易被患儿和家长所接受,可以在临床加以推广和应用。
OBJECTIVE To investigate the clinical effects of Bronchovaxom in treating children with recurrent respiratory tract infections.METHODS Totally 140 patients with recurrent respiratory tract infections were selected from Apr.2011 to May 2013 and were randomly divided into two groups,the control group with 67 cases,and 73 cases in the observation group.The control group was treated with conventional anti-infective therapy,while children in the observation group were given Bronchovaxom orally on the basis of the control group.The evaluation of the therapeutic effect of the two groups of children was conducted in the 7th day.SPSS13.0software was adopted for statistical analysis.RESULTS The total curative rate in the observation group（94.52%）was obviously higher than the control group（80.60%）.The difference was significant（P〈0.05）.The temperature decline,respiratory symptoms remission,pulmonary rales disappearance time was（1.68±0.52）d,（2.54±0.73）d and（4.38±1.42）d in the observation group,which was significantly shorter than the control group,which was（2.26±0.65）d,（3.93±0.75）d and（6.67±0.92）d.In the follow-up 6months,the times of re-episodes of respiratory tract infection in the observation group was（1.80±0.55）,which was significantly less than the control group（6.92±1.72）.The difference between the two groups was significant（P〈0.05）.After treatment,the serum immunoglobulin level of the control group did not change significantly,the IgG level of the observation group was（7.35±0.59）g/L after the treatment,which was apparently higher than before（5.41±0.84）g/L.The difference was significant（P〈0.05）,other indexes did not change remarkably.After the treatment,the IgG level in the observation group was significantly higher than the control group,which was（5.62±0.57）g/L.The result was with significance（P〈0.05）.CONCLUSIONThe application of Bronchovaxom is beneficial for the improvement of immunity,shortage of courses,perfection of prognosis and convenience of administration in treating children with recurrent respiratory tract infections,and is easily accepted by children and their parents,thus can be promoted and applied in clinical practice.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2015年第4期942-944,共3页
Chinese Journal of Nosocomiology
基金
河南省卫生厅基金资助项目(HW-2010B029)
关键词
泛福舒
儿童
呼吸道感染
Bronchovaxom
Children
Respiratory tract infection
